• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.健康成年人急性口服大麻后尿液中11-去甲-9-羧基-Δ⁹-四氢大麻酚的药代动力学特征
J Anal Toxicol. 2018 May 1;42(4):232-247. doi: 10.1093/jat/bkx102.
2
Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.非频繁使用者吸食和蒸发大麻后 11-去甲-9-羧基-Δ9-四氢大麻酚(THCCOOH)的尿液排泄特征。
J Anal Toxicol. 2020 Jan 7;44(1):1-14. doi: 10.1093/jat/bkz038.
3
Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females.大麻布朗尼的药代动力学:对健康成年男性和女性血液和口腔液中 Δ9-四氢大麻酚和代谢物的对照研究。
J Anal Toxicol. 2020 Oct 12;44(7):661-671. doi: 10.1093/jat/bkaa067.
4
Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.口服和蒸发型 CBD 以及以 CBD 为主的蒸发型大麻给药后,大麻二酚(CBD)、Δ9-四氢大麻酚(THC)及其代谢物的尿药代谢动力学特征。
J Anal Toxicol. 2022 May 20;46(5):494-503. doi: 10.1093/jat/bkab059.
5
Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana.单次吸食大麻剂量后人体中11-去甲-9-羧基-Δ⁹-四氢大麻酚的尿排泄情况
J Anal Toxicol. 1996 Oct;20(6):441-52. doi: 10.1093/jat/20.6.441.
6
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans.对人类口服受控剂量的δ9-四氢大麻酚后尿液中大麻素的检测时间。
Clin Chem. 2003 Jul;49(7):1114-24. doi: 10.1373/49.7.1114.
7
Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.口服Δ⁹-四氢大麻酚后11-去甲-9-羧基-Δ⁹-四氢大麻酚的尿液药代动力学
J Anal Toxicol. 2004 Apr;28(3):160-7. doi: 10.1093/jat/28.3.160.
8
Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes.男性志愿者吸食大麻后体内的 Delta9-四氢大麻酚及其代谢物 11-羟基-Delta9-四氢大麻酚和 11-去甲-9-羧基-Delta9-四氢大麻酚的血浆和尿液特征,以估计运动员近期的使用情况。
Anal Bioanal Chem. 2010 Apr;396(7):2493-502. doi: 10.1007/s00216-009-3431-3. Epub 2010 Jan 30.
9
Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana.单次吸食和口服大麻后通过唾液和尿液分析检测大麻使用情况。
J Anal Toxicol. 2001 Jul-Aug;25(5):289-303. doi: 10.1093/jat/25.5.289.
10
Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.慢性大麻使用者尿液中Δ9-四氢大麻酚排泄时间延长,使其无法用作新药暴露的生物标志物。
Drug Alcohol Depend. 2009 Nov 1;105(1-2):24-32. doi: 10.1016/j.drugalcdep.2009.05.027. Epub 2009 Jul 23.

引用本文的文献

1
Cannabis: Zone Aspects of Raw Plant Components in Sport-A Narrative Review.大麻:体育赛事中未加工植物成分的区域相关情况——一篇叙述性综述
Nutrients. 2025 Feb 28;17(5):861. doi: 10.3390/nu17050861.
2
Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.评估口服给予 Δ9-四氢大麻酚与大麻二酚联合使用对健康成年人中 Δ9-四氢大麻酚药代动力学和药效学的影响:一项随机临床试验。
JAMA Netw Open. 2023 Feb 1;6(2):e2254752. doi: 10.1001/jamanetworkopen.2022.54752.
3
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.医用大麻素:基于药理学的系统评价和荟萃分析,涵盖所有相关医学适应证。
BMC Med. 2022 Aug 19;20(1):259. doi: 10.1186/s12916-022-02459-1.
4
Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.非频繁大麻使用者经口摄入及吸食大麻后尿中大麻分析物排泄特征。
J Anal Toxicol. 2022 Oct 14;46(8):882-890. doi: 10.1093/jat/bkac042.
5
Cannabidiol (CBD) product contamination: Quantitative analysis of Δ-tetrahydrocannabinol (Δ-THC) concentrations found in commercially available CBD products.大麻二酚 (CBD) 产品污染:市售 CBD 产品中发现的 Δ-四氢大麻酚 (Δ-THC) 浓度的定量分析。
Drug Alcohol Depend. 2022 Aug 1;237:109522. doi: 10.1016/j.drugalcdep.2022.109522. Epub 2022 Jun 3.
6
Preliminary Evidence for Cannabis and Nicotine Urinary Metabolites as Predictors of Verbal Memory Performance and Learning Among Young Adults.大麻和尼古丁尿液代谢物作为年轻成年人言语记忆表现和学习的预测指标的初步证据。
J Int Neuropsychol Soc. 2021 Jul;27(6):546-558. doi: 10.1017/S1355617721000205.
7
Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer, in Detecting Cannabis Psychoactive Effects.新型基于脑电图的客观测试,即 Cognalyzer,在检测大麻精神活性效应中的敏感性、特异性和准确性。
Adv Ther. 2021 May;38(5):2513-2531. doi: 10.1007/s12325-021-01718-6. Epub 2021 Apr 7.
8
Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.在经常和偶尔吸食大麻的人群中,经受控吸烟、蒸发和口服大麻给药后尿液中游离型和葡糖苷酸型大麻素。
J Anal Toxicol. 2020 Oct 12;44(7):651-660. doi: 10.1093/jat/bkaa046.
9
Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.非频繁使用者吸食和蒸发大麻后 11-去甲-9-羧基-Δ9-四氢大麻酚(THCCOOH)的尿液排泄特征。
J Anal Toxicol. 2020 Jan 7;44(1):1-14. doi: 10.1093/jat/bkz038.
10
Cannabinoids from L.: A New Tool Based on HPLC-DAD-MS/MS for a Rational Use in Medicinal Chemistry.来自大麻属植物的大麻素:一种基于高效液相色谱-二极管阵列检测-串联质谱的新工具,用于药物化学中的合理应用。
ACS Med Chem Lett. 2019 Jan 29;10(4):539-544. doi: 10.1021/acsmedchemlett.8b00571. eCollection 2019 Apr 11.

本文引用的文献

1
Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.口服大麻在人体中的药代动力学特征:血液和口腔液中的分布及其与药效学结果的关系。
J Anal Toxicol. 2017 Mar 1;41(2):83-99. doi: 10.1093/jat/bkx012.
2
Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys.2002 - 2014年美国成年人使用大麻及大麻使用障碍情况:年度横断面调查分析
Lancet Psychiatry. 2016 Oct;3(10):954-964. doi: 10.1016/S2215-0366(16)30208-5. Epub 2016 Aug 31.
3
Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013.2001 - 2002年至2012 - 2013年期间美国大麻使用障碍的患病率。
JAMA Psychiatry. 2015 Dec;72(12):1235-42. doi: 10.1001/jamapsychiatry.2015.1858.
4
Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use.一种同时针对大麻和烟草使用的计算机辅助干预的结果。
Drug Alcohol Depend. 2015 Oct 1;155:134-40. doi: 10.1016/j.drugalcdep.2015.08.001. Epub 2015 Aug 10.
5
Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use.大量使用大麻后血液、尿液和口腔液中的残留大麻水平。
Forensic Sci Int. 2015 Apr;249:173-80. doi: 10.1016/j.forsciint.2015.01.026. Epub 2015 Jan 30.
6
Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results.非吸烟者接触二手大麻烟雾。I. 尿液筛查与确认结果。
J Anal Toxicol. 2015 Jan-Feb;39(1):1-12. doi: 10.1093/jat/bku116. Epub 2014 Oct 17.
7
Perceived harm, addictiveness, and social acceptability of tobacco products and marijuana among young adults: marijuana, hookah, and electronic cigarettes win.年轻人对烟草制品和大麻的感知危害、成瘾性及社会接受度:大麻、水烟和电子烟胜出。
Subst Use Misuse. 2015 Jan;50(1):79-89. doi: 10.3109/10826084.2014.958857. Epub 2014 Sep 30.
8
Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.实现大麻戒断——评估N-乙酰半胱氨酸治疗(ACCENT):美国国立药物滥用研究所临床试验网络中一项多中心随机对照研究的设计与实施
Contemp Clin Trials. 2014 Nov;39(2):211-23. doi: 10.1016/j.cct.2014.08.011. Epub 2014 Aug 30.
9
Testing for cannabis in the work-place: a review of the evidence.工作场所的大麻检测:证据回顾。
Addiction. 2010 Mar;105(3):408-16. doi: 10.1111/j.1360-0443.2009.02808.x.
10
Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?大麻素 Delta9-四氢大麻酚浓度能否反映慢性大麻使用者近期的使用情况?
Addiction. 2009 Dec;104(12):2041-8. doi: 10.1111/j.1360-0443.2009.02705.x. Epub 2009 Oct 5.

健康成年人急性口服大麻后尿液中11-去甲-9-羧基-Δ⁹-四氢大麻酚的药代动力学特征

Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

作者信息

Schlienz Nicolas J, Cone Edward J, Herrmann Evan S, Lembeck Natalie A, Mitchell John M, Bigelow George E, Flegel Ronald, LoDico Charles P, Hayes Eugene D, Vandrey Ryan

机构信息

Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA.

Battelle Memorial Institute, 6115 Falls Road, Suite 200, Baltimore, MD 21209, USA.

出版信息

J Anal Toxicol. 2018 May 1;42(4):232-247. doi: 10.1093/jat/bkx102.

DOI:10.1093/jat/bkx102
PMID:29300962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5907340/
Abstract

Understanding the urine excretion profile for Δ9-tetrahydrocannabinol (THC) metabolites is important for accurate detection and interpretation of toxicological testing for cannabis use. Prior literature has primarily evaluated the urinary pharmacokinetics of the non-psychoactive THC metabolite 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) following smoked cannabis administration. The present study examined the urine THCCOOH excretion profile following oral cannabis administration in 18 healthy adults. Following ingestion of a cannabis-containing brownie with 10, 25 or 50 mg of THC (N = 6 per dose), urine specimens were collected on a closed residential research unit for 6 days, followed by three outpatient visits on Days 7-9. Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively. Detection windows to first positive and last positive varied as a function of dose; higher doses had shorter time to first positive and longer time to last positive. Considerable inter-subject variability was observed on study outcomes. Gas chromatography/mass spectrometry (GC/MS; 15 ng/mL cutoff) was used as the criterion to assess sensitivity, specificity and agreement for THCCOOH qualitative immunoassay tests using 20, 50 and 100 ng/mL cutoffs. The 50 ng/mL cutoff displayed good sensitivity (92.5%), specificity (92.4%) and overall agreement (92.4%), whereas the 20 ng/mL cutoff demonstrated poor specificity (58.4%), and the 100 ng/mL cutoff exhibited reduced sensitivity (70.9%). Ingestion of cannabis brownies containing the 10 and 25 mg THC doses yielded THCCOOH concentrations that differed in magnitude and time course from those previously reported for the smoked route of administration of comparable doses.

摘要

了解Δ9-四氢大麻酚(THC)代谢物的尿液排泄情况对于准确检测和解释大麻使用的毒理学检测结果至关重要。先前的文献主要评估了吸食大麻后非精神活性THC代谢物11-去甲-9-羧基-Δ9-四氢大麻酚(THCCOOH)的尿药代动力学。本研究检测了18名健康成年人口服大麻后尿液中THCCOOH的排泄情况。在摄入含有10、25或50毫克THC的大麻布朗尼后(每剂量6人),在封闭的住宅研究单元收集尿液样本6天,随后在第7至9天进行三次门诊随访。THCCOOH的平均最大浓度(Cmax)分别为107、335和713纳克/毫升,10、25和50毫克THC剂量的平均达峰时间(Tmax)分别为8、6和9小时。首次阳性和末次阳性的检测窗口因剂量而异;较高剂量的首次阳性时间较短,末次阳性时间较长。在研究结果上观察到相当大的个体间差异。使用气相色谱/质谱法(GC/MS;截断值为15纳克/毫升)作为标准,评估截断值为20、50和100纳克/毫升的THCCOOH定性免疫分析测试的敏感性、特异性和一致性。50纳克/毫升的截断值显示出良好的敏感性(92.5%)、特异性(92.4%)和总体一致性(92.4%),而20纳克/毫升的截断值特异性较差(58.4%),100纳克/毫升的截断值敏感性降低(70.9%)。摄入含有10和25毫克THC剂量的大麻布朗尼后产生的THCCOOH浓度在幅度和时间进程上与先前报道的同等剂量吸食途径的浓度不同。